Last week, from 5 to 9 March, the groundbreaking series of Alzheimer’s and Parkinson’s disease (AD/PD 2024) conferences took place in Lisbon, at Centro de Congressos de Lisboa.

AD/PD™ works towards advancing innovative strategies in therapy, prevention, clinical trials and diagnostic markers, in order to focus on driving successful collaborations among academia and industry, leading to the development of innovative therapies and ultimately providing a better future for patients and families affected by neurodegenerative diseases.

WG5 leader, Inês Figueira, was present at AD/PD to broadcast IMMUPARKNET COST Action and the importance to study immune response in Parkinson’s disease progression to researchers, clinicians and stakeholders in the field.

WG5 leader, Inês Figueira, at AD/PD 2024

Share this post


Latest Updates


IMMUPARKNET WG5 article entitled “IMMUnity Unveiled: A Translational NETwork for tackling PARKinson’s Disease – IMMUPARKNET” has just been published on Open Research Europe.  The Open Letter...

Senza titolo

IMMUPARKNET COST Action recently concluded the first training school entitled “Models for Parkinson’s Disease: From Basics to Translation” held at the Faculty of Health Sciences,...

Figure 1 COST

It is with great pleasure that we anounce that Work Group 1’s IMMUPARKNET paper has been published in Brain, entitled: “The immune system in Parkinson’s...

The Art of Living

Short-term Scientific Missions (STSM) are institutional visits aimed at supporting individual mobility and fostering collaborations by allowing scientists to visit an institution and contribute to...

WG2 animal

We’re thrilled to share the latest publication from our Working Group 2 (WG2) at IMMUPARKNET COST Action 21117! Entitled “Experimental Models to Study Immune Dysfunction...


🎉 Exciting News from IMMUPARKNET COST Action 21117 Annual Meeting! 🎉 This year’s IMMUPARKNET COST Action Annual Conference took place in the beautiful city of...